|
US3557142A
(en)
|
1968-02-20 |
1971-01-19 |
Sterling Drug Inc |
4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
|
|
BE790679A
(fr)
|
1971-11-03 |
1973-04-27 |
Ici Ltd |
Derives de l'indole
|
|
DK151884C
(da)
|
1979-03-07 |
1988-06-13 |
Pfizer |
Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
|
|
US4363912A
(en)
*
|
1980-12-15 |
1982-12-14 |
Pfizer Inc. |
Indole thromboxane synthetase inhibitors
|
|
US4478842A
(en)
|
1981-11-19 |
1984-10-23 |
Ciba-Geigy Corporation |
N-Substituted-2-pyridylindoles
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
DE3514696A1
(de)
|
1985-04-24 |
1986-11-06 |
Bayer Ag, 5090 Leverkusen |
N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
|
|
US5214059A
(en)
|
1989-07-03 |
1993-05-25 |
Hoechst-Roussel Pharmaceuticals Incorporated |
2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
|
|
GB9122590D0
(en)
|
1991-10-24 |
1991-12-04 |
Lilly Industries Ltd |
Pharmaceutical compounds
|
|
EP0639567A1
(en)
|
1992-05-08 |
1995-02-22 |
Otsuka Pharmaceutical Factory, Inc. |
Indole derivative
|
|
IL109309A
(en)
|
1993-04-16 |
2000-06-29 |
Lilly Co Eli |
1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
|
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
|
US5641800A
(en)
|
1994-07-21 |
1997-06-24 |
Eli Lilly And Company |
1H-indole-1-functional sPLA2 inhibitors
|
|
US5532237A
(en)
|
1995-02-15 |
1996-07-02 |
Merck Frosst Canada, Inc. |
Indole derivatives with affinity for the cannabinoid receptor
|
|
WO1997046677A1
(fr)
|
1996-06-05 |
1997-12-11 |
Bml, Inc. |
PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6916841B2
(en)
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6500853B1
(en)
|
1998-02-28 |
2002-12-31 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6214991B1
(en)
|
1998-03-31 |
2001-04-10 |
The Institute For Pharmaceutical Discovery, Inc. |
Substituted indolealkanoic acids
|
|
PL198983B1
(pl)
|
1998-04-28 |
2008-08-29 |
Elbion Ag |
Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania
|
|
EP0984012A3
(en)
|
1998-08-31 |
2001-01-10 |
Pfizer Products Inc. |
Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
|
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
|
WO2001014882A1
(fr)
|
1999-08-23 |
2001-03-01 |
Bml, Inc. |
Identification des proprietes d'une substance pour les recepteurs de prostaglandine d
|
|
WO2001051489A2
(en)
|
2000-01-14 |
2001-07-19 |
The Institutes For Pharmaceutical Discovery, Llc |
Methods for lowering uric acid levels
|
|
AU2001238718A1
(en)
|
2000-03-02 |
2001-09-12 |
The Institutes For Pharmaceutical Discovery, Llc |
Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
|
|
JP2001247570A
(ja)
|
2000-03-08 |
2001-09-11 |
Japan Tobacco Inc |
インドール酢酸化合物及びその製造方法
|
|
US6878522B2
(en)
|
2000-07-07 |
2005-04-12 |
Baiyong Li |
Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
|
|
US6797708B2
(en)
|
2001-12-03 |
2004-09-28 |
Wyeth |
Inhibitors of cytosolic phospholipase A2
|
|
SE0200411D0
(sv)
|
2002-02-05 |
2002-02-05 |
Astrazeneca Ab |
Novel use
|
|
AU2003231509A1
(en)
|
2002-05-16 |
2003-12-02 |
Shionogi And Co., Ltd. |
Compound exhibiting pgd 2 receptor antagonism
|
|
SE0201635D0
(sv)
|
2002-05-30 |
2002-05-30 |
Astrazeneca Ab |
Novel compounds
|
|
TW200307542A
(en)
|
2002-05-30 |
2003-12-16 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202241D0
(sv)
|
2002-07-17 |
2002-07-17 |
Astrazeneca Ab |
Novel Compounds
|
|
CA2509170A1
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
|
PL377314A1
(pl)
|
2002-12-20 |
2006-01-23 |
Amgen Inc. |
Modulatory astmy i zapaleń na tle alergicznym
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302232D0
(sv)
|
2003-08-18 |
2003-08-18 |
Astrazeneca Ab |
Novel Compounds
|
|
US20070232681A1
(en)
|
2003-10-14 |
2007-10-04 |
Oxagen Limited |
Compounds Having Crth2 Antagonist Activity
|
|
GB0324763D0
(en)
|
2003-10-23 |
2003-11-26 |
Oxagen Ltd |
Use of compounds in therapy
|
|
AU2004291259A1
(en)
|
2003-11-05 |
2005-06-02 |
F. Hoffmann-La Roche Ag |
Heteroaryl derivatives as PPAR activators
|
|
SE0303180D0
(sv)
|
2003-11-26 |
2003-11-26 |
Astrazeneca Ab |
Novel compounds
|
|
MXPA06011891A
(es)
*
|
2004-04-20 |
2007-04-24 |
Pfizer |
Metodo para tratar el dolor neuropatico.
|
|
JP4793692B2
(ja)
|
2004-04-26 |
2011-10-12 |
小野薬品工業株式会社 |
新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
|
|
GB0412914D0
(en)
|
2004-06-10 |
2004-07-14 |
Oxagen Ltd |
Compounds
|
|
WO2006034419A2
(en)
|
2004-09-21 |
2006-03-30 |
Athersys, Inc. |
Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
|
|
GB2422830A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB2422829A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB2422831A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB0504150D0
(en)
|
2005-03-01 |
2005-04-06 |
Oxagen Ltd |
Microcrystalline material
|
|
GB0505048D0
(en)
|
2005-03-11 |
2005-04-20 |
Oxagen Ltd |
Compounds with PGD antagonist activity
|
|
EP2397476A3
(en)
|
2005-07-22 |
2011-12-28 |
Shionogi & Co., Ltd. |
Indole derivative having PGD2 receptor antagonist activity
|
|
US7696222B2
(en)
|
2005-08-12 |
2010-04-13 |
Merck Frosst Canada Ltd |
Indole derivatives as CRTH2 receptor antagonists
|
|
GB0518783D0
(en)
|
2005-09-14 |
2005-10-26 |
Argenta Discovery Ltd |
Indolizine compounds
|
|
GB0605743D0
(en)
|
2006-03-22 |
2006-05-03 |
Oxagen Ltd |
Salts with CRTH2 antagonist activity
|
|
GB0614068D0
(en)
|
2006-07-14 |
2006-08-23 |
Glaxo Group Ltd |
Compounds
|
|
GB0614066D0
(en)
|
2006-07-14 |
2006-08-23 |
Glaxo Group Ltd |
Compounds
|
|
CA2658496A1
(en)
|
2006-07-22 |
2008-01-31 |
Oxagen Limited |
2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
|
|
WO2009037503A2
(en)
|
2007-09-18 |
2009-03-26 |
Astrazeneca Ab |
New combination - 012 for the treatment of respiratory diseases
|
|
GB0722216D0
(en)
|
2007-11-13 |
2007-12-27 |
Oxagen Ltd |
Use of crth2 antagonist compounds
|
|
GB0722203D0
(en)
|
2007-11-13 |
2007-12-19 |
Oxagen Ltd |
Use of CRTH2 antagonist compounds
|
|
DK2229358T3
(da)
|
2007-12-14 |
2011-07-04 |
Pulmagen Therapeutics Asthma Ltd |
Indoler og deres terapeutiske anvendelse
|
|
WO2009090399A1
(en)
|
2008-01-18 |
2009-07-23 |
Argenta Discovery Limited |
Indoles active on crth2 receptor
|
|
US7750027B2
(en)
|
2008-01-18 |
2010-07-06 |
Oxagen Limited |
Compounds having CRTH2 antagonist activity
|
|
CA2712017C
(en)
*
|
2008-01-18 |
2016-08-09 |
Oxagen Limited |
Compounds having crth2 antagonist activity
|
|
EP2265581A1
(en)
|
2008-01-22 |
2010-12-29 |
Oxagen Limited |
Compounds having crth2 antagonist activity
|
|
JP2011509991A
(ja)
|
2008-01-22 |
2011-03-31 |
オキサジェン リミテッド |
Ｃｒｔｈ２アンタゴニスト活性を有する化合物
|
|
WO2010008864A2
(en)
|
2008-06-24 |
2010-01-21 |
Amira Pharmaceuticals, Inc. |
Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
|
|
GB201103837D0
(en)
|
2011-03-07 |
2011-04-20 |
Oxagen Ltd |
Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
|
|
GB201121557D0
(en)
*
|
2011-12-15 |
2012-01-25 |
Oxagen Ltd |
Process
|
|
SG11201402796SA
(en)
|
2011-12-16 |
2014-06-27 |
Atopix Therapeutics Ltd |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
|
GB201322273D0
(en)
|
2013-12-17 |
2014-01-29 |
Atopix Therapeutics Ltd |
Process
|
|
GB201407813D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|
|
GB201407807D0
(en)
*
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|